The Children’s Tumor Foundation is an Associated Partner of the European-based Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI), a jointly funded partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), will soon issue a call for an integrated research platform enabling patient-centric drug development.
Study Shows that Drug Combination Therapies Effective in Treating Schwannomas and Meningiomas
The Synodos for NF2 consortium of the Children’s Tumor Foundation (CTF) today published its first set of results and released its second set of data in the leading scientific journal PLOS ONE.
The Children’s Tumor Foundation (CTF), the largest non-governmental funder of neurofibromatosis (NF) research, and PLOS ONE, a leading peer-reviewed scientific journal, are pleased to announce the successful completion of the first funding cycle of the Drug Discovery Initiative Registered Report (DDIRR) 2017 Awards, a funder-publisher partnership integrating the Registered Reports model into the grant application process.
On May 17, hundreds of landmarks around the world will “Shine a Light on NF” to raise awareness for genetic disorder that causes tumors and has no cure at this time
NEW YORK – May 17, 2018 – The Children’s Tumor Foundation is pleased to announce that in recognition of NF Awareness Month architectural icons across the globe will show their support in the fight against neurofibromatosis (NF) by lighting up in blue and green, the official colors of the NF cause.
The Children’s Tumor Foundation 'I Know a Fighter’ Initiative Brings Attention to Brave Heroes Battling Rare Genetic Disorder
NEW YORK – May 1, 2018 – Neurofibromatosis, or NF, is a genetic disorder that few have heard of, yet it affects over 125,000 Americans and over 2.5 million people worldwide. The Children’s Tumor Foundation is working to change that through a month-long campaign drawing attention to the inspirational and remarkable stories of those living with NF, and the critical need for research to better their lives.